BTAI BioXcel Therapeutics | $3.52
-7.3% | 3/19/2025 | Elemer Piros | Initiated Coverage | Buy | $65.00 | View details for Rodman & Renshaw rating of BioXcel Therapeutics (NASDAQ:BTAI) on 3/19/2025 |
TELO Telomir Pharmaceuticals | $1.19
-1.3% | 2/21/2025 | - | Initiated Coverage | Buy | $15.00 | View details for Rodman & Renshaw rating of Telomir Pharmaceuticals (NASDAQ:TELO) on 2/21/2025 |
TLPH Talphera | $0.53
-2.8% | 1/28/2025 | - | Initiated Coverage | Buy | $4.00 | View details for Rodman & Renshaw rating of Talphera (NASDAQ:TLPH) on 1/28/2025 |
PYPD PolyPid | $3.42
+0.1% | 1/28/2025 | - | Initiated Coverage | Buy | $13.00 | View details for Rodman & Renshaw rating of PolyPid (NASDAQ:PYPD) on 1/28/2025 |
INMB INmune Bio | $1.98
+0.3% | 1/28/2025 | - | Initiated Coverage | Buy | $23.00 | View details for Rodman & Renshaw rating of INmune Bio (NASDAQ:INMB) on 1/28/2025 |
CRDL Cardiol Therapeutics | $1.10
| 1/28/2025 | - | Initiated Coverage | Buy | $7.00 | View details for Rodman & Renshaw rating of Cardiol Therapeutics (NASDAQ:CRDL) on 1/28/2025 |
ATRA Atara Biotherapeutics | $12.30
-0.3% | 12/20/2024 | - | Initiated Coverage | Buy | $25.00 | View details for Rodman & Renshaw rating of Atara Biotherapeutics (NASDAQ:ATRA) on 12/20/2024 |
HURA TuHURA Biosciences | $2.58
-0.5% | 12/19/2024 | - | Initiated Coverage | Buy | $11.00 | View details for Rodman & Renshaw rating of TuHURA Biosciences (NASDAQ:HURA) on 12/19/2024 |
FBLG FibroBiologics | $0.60
-3.1% | 12/12/2024 | - | Initiated Coverage | Buy | $12.00 | View details for Rodman & Renshaw rating of FibroBiologics (NASDAQ:FBLG) on 12/12/2024 |
THAR Tharimmune | $4.59
-11.7% | 12/6/2024 | - | Initiated Coverage | Buy | $17.00 | View details for Rodman & Renshaw rating of Tharimmune (NASDAQ:THAR) on 12/6/2024 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
RMTI Rockwell Medical | $1.77
-3.5% | 11/14/2024 | - | Initiated Coverage | Buy | $5.00 | View details for Rodman & Renshaw rating of Rockwell Medical (NASDAQ:RMTI) on 11/14/2024 |
OMER Omeros | $4.10
-4.5% | 11/14/2024 | - | Initiated Coverage | Buy | $9.00 | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 11/14/2024 |
EPRX Eupraxia Pharmaceuticals | $5.40
-0.3% | 11/14/2024 | - | Initiated Coverage | Buy | $9.00 | View details for Rodman & Renshaw rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 11/14/2024 |
ACHV Achieve Life Sciences | $2.91
-0.5% | 11/14/2024 | - | Initiated Coverage | Buy | $12.00 | View details for Rodman & Renshaw rating of Achieve Life Sciences (NASDAQ:ACHV) on 11/14/2024 |
BCAX Bicara Therapeutics | $11.95
+0.4% | 11/5/2024 | - | Initiated Coverage | Buy | $48.00 | View details for Rodman & Renshaw rating of Bicara Therapeutics (NASDAQ:BCAX) on 11/5/2024 |
QNCX Quince Therapeutics | $1.60
-0.3% | 10/29/2024 | - | Initiated Coverage | Buy | $11.00 | View details for Rodman & Renshaw rating of Quince Therapeutics (NASDAQ:QNCX) on 10/29/2024 |
ANRO Alto Neuroscience | $3.73
-4.0% | 10/23/2024 | - | Downgrade | Buy -> Neutral | | View details for Rodman & Renshaw rating of Alto Neuroscience (NYSE:ANRO) on 10/23/2024 |
MNPR Monopar Therapeutics | $36.04
+6.2% | 10/11/2024 | - | Initiated Coverage | Buy | $50.00 | View details for Rodman & Renshaw rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/11/2024 |
NKTX Nkarta | $2.12
+0.7% | 10/9/2024 | - | Initiated Coverage | Buy | $14.00 | View details for Rodman & Renshaw rating of Nkarta (NASDAQ:NKTX) on 10/9/2024 |
KYTX Kyverna Therapeutics | $3.59
| 10/9/2024 | - | Initiated Coverage | Buy | $16.00 | View details for Rodman & Renshaw rating of Kyverna Therapeutics (NASDAQ:KYTX) on 10/9/2024 |
MIRA MIRA Pharmaceuticals | $1.39
-0.6% | 9/30/2024 | - | Initiated Coverage | Buy | $17.00 | View details for Rodman & Renshaw rating of MIRA Pharmaceuticals (NASDAQ:MIRA) on 9/30/2024 |
BMEA Biomea Fusion | $1.97
-3.2% | 9/26/2024 | - | Upgrade | Neutral -> Buy | $18.00 | View details for Rodman & Renshaw rating of Biomea Fusion (NASDAQ:BMEA) on 9/26/2024 |
EBS Emergent Biosolutions | $8.03
-2.3% | 9/13/2024 | - | Reiterated Rating | Buy -> Buy | $16.00 -> $16.00 | View details for Rodman & Renshaw rating of Emergent Biosolutions (NYSE:EBS) on 9/13/2024 |
ATHA Athira Pharma | $0.39
+1.8% | 9/4/2024 | - | Downgrade | Buy -> Neutral | | View details for Rodman & Renshaw rating of Athira Pharma (NASDAQ:ATHA) on 9/4/2024 |
PASG Passage Bio | $7.39
+4.0% | 9/3/2024 | - | Initiated Coverage | Buy | $140.00 | View details for Rodman & Renshaw rating of Passage Bio (NASDAQ:PASG) on 9/3/2024 |
CRMD CorMedix | $14.20
-3.0% | 8/26/2024 | - | Initiated Coverage | Buy | $13.00 | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 8/26/2024 |
MIST Milestone Pharmaceuticals | $1.80
-2.4% | 8/22/2024 | - | Initiated Coverage | Buy | $9.00 | View details for Rodman & Renshaw rating of Milestone Pharmaceuticals (NASDAQ:MIST) on 8/22/2024 |
DERM Journey Medical | $7.05
-1.0% | 8/22/2024 | - | Initiated Coverage | Buy | $9.00 | View details for Rodman & Renshaw rating of Journey Medical (NASDAQ:DERM) on 8/22/2024 |
EBS Emergent Biosolutions | $8.03
-2.3% | 8/22/2024 | - | Initiated Coverage | Buy | $16.00 | View details for Rodman & Renshaw rating of Emergent Biosolutions (NYSE:EBS) on 8/22/2024 |
ATHA Athira Pharma | $0.39
+1.8% | 8/19/2024 | - | Initiated Coverage | Buy | $22.00 | View details for Rodman & Renshaw rating of Athira Pharma (NASDAQ:ATHA) on 8/19/2024 |
SAVA Cassava Sciences | $2.23
-2.0% | 8/8/2024 | - | Reiterated Rating | Buy -> Buy | $107.00 -> $107.00 | View details for Rodman & Renshaw rating of Cassava Sciences (NASDAQ:SAVA) on 8/8/2024 |
IPSC Century Therapeutics | $0.48
-0.2% | 8/8/2024 | - | Initiated Coverage | Buy | $6.00 | View details for Rodman & Renshaw rating of Century Therapeutics (NASDAQ:IPSC) on 8/8/2024 |
CRSP CRISPR Therapeutics | $52.96
+0.6% | 8/2/2024 | - | Initiated Coverage | Buy | $90.00 | View details for Rodman & Renshaw rating of CRISPR Therapeutics (NASDAQ:CRSP) on 8/2/2024 |
ANVS Annovis Bio | $2.31
-0.9% | 7/2/2024 | - | Reiterated Rating | Buy -> Buy | $67.00 -> $67.00 | View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 7/2/2024 |
CGTX Cognition Therapeutics | $2.33
-4.1% | 7/2/2024 | - | Reiterated Rating | Buy -> Buy | $14.00 -> $14.00 | View details for Rodman & Renshaw rating of Cognition Therapeutics (NASDAQ:CGTX) on 7/2/2024 |
NKTR Nektar Therapeutics | $28.27
-2.8% | 6/28/2024 | - | Initiated Coverage | Buy | $30.00 | View details for Rodman & Renshaw rating of Nektar Therapeutics (NASDAQ:NKTR) on 6/28/2024 |
LPTX Leap Therapeutics | $0.29
-1.2% | 6/28/2024 | - | Initiated Coverage | Buy | $8.00 | View details for Rodman & Renshaw rating of Leap Therapeutics (NASDAQ:LPTX) on 6/28/2024 |
MURA Mural Oncology | $2.08
-0.2% | 6/28/2024 | - | Initiated Coverage | Buy | $15.00 | View details for Rodman & Renshaw rating of Mural Oncology (NASDAQ:MURA) on 6/28/2024 |
SANA Sana Biotechnology | $2.85
+0.2% | 6/26/2024 | - | Initiated Coverage | Buy | $16.00 | View details for Rodman & Renshaw rating of Sana Biotechnology (NASDAQ:SANA) on 6/26/2024 |
ANRO Alto Neuroscience | $3.73
-4.0% | 6/21/2024 | - | Initiated Coverage | Buy | $43.00 | View details for Rodman & Renshaw rating of Alto Neuroscience (NYSE:ANRO) on 6/21/2024 |
BREAKING: The House just passed 3 pro-crypto bills! (Ad) THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.  Discover the under-the-radar project I believe will skyrocket as a result. |
COYA Coya Therapeutics | $6.65
+1.9% | 6/13/2024 | - | Initiated Coverage | Buy | $18.00 | View details for Rodman & Renshaw rating of Coya Therapeutics (NASDAQ:COYA) on 6/13/2024 |
TRVI Trevi Therapeutics | $7.31
+0.5% | 6/13/2024 | - | Initiated Coverage | Buy | $7.00 | View details for Rodman & Renshaw rating of Trevi Therapeutics (NASDAQ:TRVI) on 6/13/2024 |
SCLX Scilex | $18.67
+0.2% | 6/13/2024 | - | Initiated Coverage | Buy | $455.00 | View details for Rodman & Renshaw rating of Scilex (NASDAQ:SCLX) on 6/13/2024 |
RANI Rani Therapeutics | $0.49
+5.6% | 6/13/2024 | - | Initiated Coverage | Buy | $10.00 | View details for Rodman & Renshaw rating of Rani Therapeutics (NASDAQ:RANI) on 6/13/2024 |
MNKD MannKind | $5.63
-2.0% | 6/13/2024 | - | Initiated Coverage | Buy | $8.00 | View details for Rodman & Renshaw rating of MannKind (NASDAQ:MNKD) on 6/13/2024 |
HRTX Heron Therapeutics | $1.37
+3.4% | 6/13/2024 | - | Initiated Coverage | Buy | $7.00 | View details for Rodman & Renshaw rating of Heron Therapeutics (NASDAQ:HRTX) on 6/13/2024 |
AVDL Avadel Pharmaceuticals | $14.32
-4.4% | 6/12/2024 | - | Initiated Coverage | Buy | $27.00 | View details for Rodman & Renshaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 6/12/2024 |
ANVS Annovis Bio | $2.31
-0.9% | 6/4/2024 | - | Initiated Coverage | Buy | $67.00 | View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 6/4/2024 |
BHC Bausch Health Cos | $7.44
-3.2% | 8/10/2017 | - | Reiterated Rating | Neutral | $17.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 8/10/2017 |
CRMD CorMedix | $14.20
-3.0% | 8/10/2017 | - | Lower Price Target | Buy -> Buy | $25.00 -> $15.00 | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 8/10/2017 |
GEVO Gevo | $1.67
-3.2% | 8/9/2017 | - | Reiterated Rating | Buy | $240.00 | View details for Rodman & Renshaw rating of Gevo (NASDAQ:GEVO) on 8/9/2017 |
POETF POET Technologies | $5.30
-1.1% | 8/7/2017 | - | Initiated Coverage | Buy | | View details for Rodman & Renshaw rating of POET Technologies (OTCMKTS:POETF) on 8/7/2017 |
VERU Veru | $3.35
+2.0% | 7/26/2017 | - | Initiated Coverage | Buy -> Buy | $50.00 | View details for Rodman & Renshaw rating of Veru (NASDAQ:VERU) on 7/26/2017 |
PLUG Plug Power | $1.52
+2.4% | 7/24/2017 | - | Reiterated Rating | Buy | $4.00 | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 7/24/2017 |
CAPR Capricor Therapeutics | $6.27
-0.9% | 7/22/2017 | - | Reiterated Rating | Buy | $2.15 | View details for Rodman & Renshaw rating of Capricor Therapeutics (NASDAQ:CAPR) on 7/22/2017 |
BYSI BeyondSpring | $1.81
-1.1% | 7/14/2017 | - | Boost Price Target | Buy -> Buy | $43.00 -> $50.00 | View details for Rodman & Renshaw rating of BeyondSpring (NASDAQ:BYSI) on 7/14/2017 |
FBIO Fortress Biotech | $2.97
-0.3% | 7/11/2017 | - | Initiated Coverage | Buy -> Buy | $165.00 | View details for Rodman & Renshaw rating of Fortress Biotech (NASDAQ:FBIO) on 7/11/2017 |
EMAN eMagin | $2.07
| 6/23/2017 | - | Reiterated Rating | Buy | $4.00 | View details for Rodman & Renshaw rating of eMagin (NYSEAMERICAN:EMAN) on 6/23/2017 |
USA Americas Silver | C$3.92
+3.7% | 6/15/2017 | - | Initiated Coverage | Buy | C$4.00 | View details for Rodman & Renshaw rating of Americas Silver (TSE:USA) on 6/15/2017 |
USAS Americas Gold and Silver | $2.83
+2.0% | 6/15/2017 | - | Initiated Coverage | Buy -> Buy | $10.00 -> $10.00 | View details for Rodman & Renshaw rating of Americas Gold and Silver (NYSEAMERICAN:USAS) on 6/15/2017 |
EYPT Eyepoint Pharmaceuticals | $11.95
+1.9% | 5/30/2017 | - | Initiated Coverage | Buy | $800.00 | View details for Rodman & Renshaw rating of Eyepoint Pharmaceuticals (NASDAQ:EYPT) on 5/30/2017 |
PLX Protalix BioTherapeutics | $1.64
-0.3% | 5/23/2017 | - | Reiterated Rating | Buy | $50.00 | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 5/23/2017 |
ACAD ACADIA Pharmaceuticals | $25.53
-0.6% | 5/22/2017 | - | Reiterated Rating | Buy | $60.00 | View details for Rodman & Renshaw rating of ACADIA Pharmaceuticals (NASDAQ:ACAD) on 5/22/2017 |
BHC Bausch Health Cos | $7.44
-3.2% | 5/19/2017 | - | Reiterated Rating | Neutral | $17.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 5/19/2017 |
MGIC Magic Software Enterprises | $19.34
+0.2% | 5/17/2017 | - | Reiterated Rating | Buy -> Buy | $9.00 -> $10.00 | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 5/17/2017 |
IOVA Iovance Biotherapeutics | $2.20
+0.2% | 5/10/2017 | - | Initiated Coverage | Buy -> Buy | $13.00 | View details for Rodman & Renshaw rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 5/10/2017 |
CRMD CorMedix | $14.20
-3.0% | 5/5/2017 | - | Lower Price Target | Buy | $30.00 -> $25.00 | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 5/5/2017 |
AMSC American Superconductor | $49.18
+0.9% | 4/28/2017 | - | Reiterated Rating | Buy -> Buy | $10.00 -> $7.50 | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 4/28/2017 |
B Barrick Mining | $27.16
+0.9% | 4/24/2017 | - | Boost Price Target | Buy | $4.25 -> $4.50 | View details for Rodman & Renshaw rating of Barrick Mining (NYSE:B) on 4/24/2017 |
PLX Protalix BioTherapeutics | $1.64
-0.3% | 4/17/2017 | - | Boost Price Target | Buy | $40.00 -> $50.00 | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/17/2017 |
PLX Protalix BioTherapeutics | $1.64
-0.3% | 4/17/2017 | - | Reiterated Rating | Buy -> Buy | $40.00 -> $50.00 | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/17/2017 |
WRN Western Copper and Gold | C$2.13
+5.4% | 4/10/2017 | - | Reiterated Rating | Buy | C$2.00 | View details for Rodman & Renshaw rating of Western Copper and Gold (TSE:WRN) on 4/10/2017 |
WRN Western Copper and Gold | $1.55
+4.4% | 4/7/2017 | - | Reiterated Rating | Buy | $2.00 | View details for Rodman & Renshaw rating of Western Copper and Gold (NYSEAMERICAN:WRN) on 4/7/2017 |
PLUG Plug Power | $1.52
+2.4% | 4/6/2017 | - | Boost Price Target | Buy -> Buy | $3.00 -> $4.00 | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 4/6/2017 |
BYSI BeyondSpring | $1.81
-1.1% | 4/4/2017 | - | Initiated Coverage | Buy -> Buy | $43.00 | View details for Rodman & Renshaw rating of BeyondSpring (NASDAQ:BYSI) on 4/4/2017 |
CYTK Cytokinetics | $48.39
-2.5% | 3/23/2017 | - | Reiterated Rating | Buy | $25.00 | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 3/23/2017 |
HROW Harrow | $37.35
-1.0% | 3/22/2017 | - | Reiterated Rating | Buy | $5.00 | View details for Rodman & Renshaw rating of Harrow (NASDAQ:HROW) on 3/22/2017 |
MAG MAG Silver | $24.60
-0.6% | 3/9/2017 | - | Reiterated Rating | Buy -> Buy | $20.00 -> $20.50 | View details for Rodman & Renshaw rating of MAG Silver (NYSEAMERICAN:MAG) on 3/9/2017 |
CYTK Cytokinetics | $48.39
-2.5% | 3/8/2017 | - | Initiated Coverage | Buy -> Buy | $25.00 | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 3/8/2017 |
BHC Bausch Health Cos | $7.44
-3.2% | 3/6/2017 | - | Lower Price Target | Neutral | $23.00 -> $17.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/6/2017 |
MGIC Magic Software Enterprises | $19.34
+0.2% | 3/6/2017 | - | Reiterated Rating | Buy -> Buy | $8.00 -> $9.00 | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 3/6/2017 |
QRHC Quest Resource | $1.75
-3.6% | 3/6/2017 | - | Initiated Coverage | Buy -> Buy | $5.00 | View details for Rodman & Renshaw rating of Quest Resource (NASDAQ:QRHC) on 3/6/2017 |
BHC Bausch Health Cos | $7.44
-3.2% | 2/27/2017 | - | Reiterated Rating | Neutral | $23.00 -> $17.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 2/27/2017 |
CAPR Capricor Therapeutics | $6.27
-0.9% | 2/13/2017 | - | Initiated Coverage | Buy | $14.00 | View details for Rodman & Renshaw rating of Capricor Therapeutics (NASDAQ:CAPR) on 2/13/2017 |
BLRX BioLineRx | $3.58
-4.7% | 2/13/2017 | - | Initiated Coverage | Buy | $120.00 | View details for Rodman & Renshaw rating of BioLineRx (NASDAQ:BLRX) on 2/13/2017 |
ABEO Abeona Therapeutics | $6.87
+0.2% | 2/7/2017 | ram selvaraju | Reiterated Rating | Buy | $425.00 -> $500.00 | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 2/7/2017 |
NBY NovaBay Pharmaceuticals | $2.47
+8.3% | 2/6/2017 | - | Initiated Coverage | Buy | $210.00 | View details for Rodman & Renshaw rating of NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) on 2/6/2017 |
BHC Bausch Health Cos | $7.44
-3.2% | 1/31/2017 | - | Downgrade | Buy -> Neutral | | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 1/31/2017 |
ASM Avino Silver & Gold Mines | $4.60
-1.2% | 1/24/2017 | - | Boost Price Target | Buy | $3.50 -> $4.00 | View details for Rodman & Renshaw rating of Avino Silver & Gold Mines (NYSE:ASM) on 1/24/2017 |
NAGE Niagen Bioscience | $9.70
-1.8% | 1/3/2017 | - | Initiated Coverage | Buy | $6.00 | View details for Rodman & Renshaw rating of Niagen Bioscience (NASDAQ:NAGE) on 1/3/2017 |
Forget Tesla — This Tiny AI Stock Is Musk’s Real Play (Ad) While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it could transform warfare, robotics, and the global economy. But you don’t need to buy Tesla or wait for xAI to IPO to benefit.
One overlooked public company is supplying the critical tech behind Musk’s AI push — and it trades for a fraction of Nvidia’s price. Hedge funds are already loading up, but most investors haven’t noticed yet. See the full details on this “backdoor” Musk bet here |
PLUG Plug Power | $1.52
+2.4% | 12/6/2016 | - | Initiated Coverage | Buy | $3.00 | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 12/6/2016 |
B Barrick Mining | $27.16
+0.9% | 11/28/2016 | - | Boost Price Target | Buy | $4.00 -> $4.25 | View details for Rodman & Renshaw rating of Barrick Mining (NYSE:B) on 11/28/2016 |
HROW Harrow | $37.35
-1.0% | 11/28/2016 | - | Initiated Coverage | Buy | $5.00 | View details for Rodman & Renshaw rating of Harrow (NASDAQ:HROW) on 11/28/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 11/10/2016 | Ram Selvaraju | Downgrade | Buy -> Neutral | $81.00 -> $23.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 11/10/2016 |
GGD GoGold Resources | C$2.64
+5.2% | 10/7/2016 | - | Lower Price Target | Buy | C$3.50 -> C$3.00 | View details for Rodman & Renshaw rating of GoGold Resources (TSE:GGD) on 10/7/2016 |
CYDY CytoDyn | $0.31
-2.8% | 10/6/2016 | - | Initiated Coverage | Buy | $1.60 | View details for Rodman & Renshaw rating of CytoDyn (OTCMKTS:CYDY) on 10/6/2016 |
TGEN Tecogen | $7.19
-2.8% | 10/4/2016 | - | Initiated Coverage | Buy | $6.00 | View details for Rodman & Renshaw rating of Tecogen (OTCMKTS:TGEN) on 10/4/2016 |
DRRX DURECT | $1.93
-0.8% | 9/27/2016 | Ram Selvaraju | Reiterated Rating | Buy | $40.00 -> $35.00 | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 9/27/2016 |
AYTU Aytu BioPharma | $2.34
-0.4% | 9/26/2016 | - | Initiated Coverage | Buy | $9.00 | View details for Rodman & Renshaw rating of Aytu BioPharma (NASDAQ:AYTU) on 9/26/2016 |
CLNE Clean Energy Fuels | $2.52
-3.3% | 9/23/2016 | - | Reiterated Rating | Buy | $5.00 -> $6.30 | View details for Rodman & Renshaw rating of Clean Energy Fuels (NASDAQ:CLNE) on 9/23/2016 |
UUUU Energy Fuels | $11.41
+0.4% | 9/22/2016 | - | Boost Price Target | Buy | $5.00 -> $6.30 | View details for Rodman & Renshaw rating of Energy Fuels (NYSEAMERICAN:UUUU) on 9/22/2016 |
UUUU Energy Fuels | $11.41
+0.4% | 9/22/2016 | - | Lower Price Target | Buy | $6.30 -> $5.00 | View details for Rodman & Renshaw rating of Energy Fuels (NYSEAMERICAN:UUUU) on 9/22/2016 |
VNRX VolitionRX | $0.68
+2.5% | 9/7/2016 | - | Lower Price Target | Buy | $12.00 -> $10.00 | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 9/7/2016 |
VNRX VolitionRX | $0.68
+2.5% | 9/7/2016 | Ram Selvaraju | Reiterated Rating | Buy | $12.00 -> $10.00 | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 9/7/2016 |
MEEC Midwest Energy Emissions | $0.60
+8.9% | 9/7/2016 | - | Initiated Coverage | Buy | $2.50 | View details for Rodman & Renshaw rating of Midwest Energy Emissions (OTCMKTS:MEEC) on 9/7/2016 |
HL Hecla Mining | $8.90
-0.3% | 9/6/2016 | - | Initiated Coverage | Buy | $9.00 | View details for Rodman & Renshaw rating of Hecla Mining (NYSE:HL) on 9/6/2016 |
REI Ring Energy | $1.01
-5.2% | 8/29/2016 | - | Initiated Coverage | Buy | $15.00 | View details for Rodman & Renshaw rating of Ring Energy (NYSEAMERICAN:REI) on 8/29/2016 |
DRIO DarioHealth | $9.44
+3.1% | 8/22/2016 | Ram Selvaraju | Reiterated Rating | Buy | $240.00 | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 8/22/2016 |
ORMP Oramed Pharmaceuticals | $2.19
+1.6% | 8/21/2016 | Ram Selvaraju | Reiterated Rating | Buy | $25.00 | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 8/21/2016 |
ABEO Abeona Therapeutics | $6.87
+0.2% | 8/21/2016 | - | Reiterated Rating | Buy | $425.00 | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 8/21/2016 |
SMT Sierra Metals | C$1.14
| 8/18/2016 | - | Reiterated Rating | Buy | C$3.00 | View details for Rodman & Renshaw rating of Sierra Metals (TSE:SMT) on 8/18/2016 |
EFOI Energy Focus | $2.62
+3.1% | 8/15/2016 | - | Boost Price Target | Buy | $280.00 -> $560.00 | View details for Rodman & Renshaw rating of Energy Focus (NASDAQ:EFOI) on 8/15/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 8/9/2016 | Ram Selvaraju | Lower Price Target | Buy | $90.00 -> $81.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 8/9/2016 |
ABEO Abeona Therapeutics | $6.87
+0.2% | 8/5/2016 | - | Reiterated Rating | Buy | $425.00 | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 8/5/2016 |
DRRX DURECT | $1.93
-0.8% | 8/3/2016 | Ram Selvaraju | Reiterated Rating | Buy | $40.00 | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 8/3/2016 |
EKSO Ekso Bionics | $4.11
+4.1% | 7/31/2016 | - | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of Ekso Bionics (NASDAQ:EKSO) on 7/31/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 7/28/2016 | Ram Selvaraju | Reiterated Rating | Buy | $90.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 7/28/2016 |
KURA Kura Oncology | $8.25
+3.8% | 7/18/2016 | - | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of Kura Oncology (NASDAQ:KURA) on 7/18/2016 |
F Ford Motor | $11.64
-0.7% | 7/18/2016 | - | Initiated Coverage | Buy | | View details for Rodman & Renshaw rating of Ford Motor (NYSE:F) on 7/18/2016 |
OESX Orion Energy Systems | $7.18
+2.0% | 7/18/2016 | - | Initiated Coverage | Buy | $25.00 | View details for Rodman & Renshaw rating of Orion Energy Systems (NASDAQ:OESX) on 7/18/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 7/17/2016 | Ram Selvaraju | Reiterated Rating | Buy | $90.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 7/17/2016 |
PLX Protalix BioTherapeutics | $1.64
-0.3% | 7/11/2016 | Ram Selvaraju | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 7/11/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 7/6/2016 | Ram Selvaraju | Reiterated Rating | Buy | $90.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 7/6/2016 |
DRRX DURECT | $1.93
-0.8% | 7/6/2016 | Ram Selvaraju | Reiterated Rating | Buy | $40.00 | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 7/6/2016 |
CBIO Crescent Biopharma | $13.00
-5.0% | 6/30/2016 | - | Initiated Coverage | Buy | $5,250.00 | View details for Rodman & Renshaw rating of Crescent Biopharma (NASDAQ:CBIO) on 6/30/2016 |
INO Inovio Pharmaceuticals | $2.65
+2.9% | 6/21/2016 | - | Reiterated Rating | Buy | $2,448.00 | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 6/21/2016 |
WPRT Westport Fuel Systems | $2.70
-2.2% | 6/20/2016 | - | Initiated Coverage | Buy | $50.00 | View details for Rodman & Renshaw rating of Westport Fuel Systems (NASDAQ:WPRT) on 6/20/2016 |
VNRX VolitionRX | $0.68
+2.5% | 6/16/2016 | Ram Selvaraju | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 6/16/2016 |
KURA Kura Oncology | $8.25
+3.8% | 5/24/2016 | - | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of Kura Oncology (NASDAQ:KURA) on 5/24/2016 |
DRIO DarioHealth | $9.44
+3.1% | 5/24/2016 | Ram Selvaraju | Reiterated Rating | Buy | $240.00 | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 5/24/2016 |
ABEO Abeona Therapeutics | $6.87
+0.2% | 5/18/2016 | - | Reiterated Rating | Buy | $425.00 | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 5/18/2016 |
VNRX VolitionRX | $0.68
+2.5% | 5/16/2016 | Ram Selvaraju | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 5/16/2016 |
DRRX DURECT | $1.93
-0.8% | 5/13/2016 | Ram Selvaraju | Reiterated Rating | Buy | $40.00 | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 5/13/2016 |
ORMP Oramed Pharmaceuticals | $2.19
+1.6% | 5/13/2016 | Ram Selvaraju | Reiterated Rating | Buy | $25.00 | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 5/13/2016 |
MBOT Microbot Medical | $3.61
-3.9% | 5/10/2016 | Ram Selvaraju | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of Microbot Medical (NASDAQ:MBOT) on 5/10/2016 |
DRIO DarioHealth | $9.44
+3.1% | 5/9/2016 | - | Initiated Coverage | Buy | $240.00 | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 5/9/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 5/3/2016 | Ram Selvaraju | Lower Price Target | Buy | $105.00 -> $102.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 5/3/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 4/26/2016 | Ram Selvaraju | Reiterated Rating | Buy | $105.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 4/26/2016 |
DRRX DURECT | $1.93
-0.8% | 4/25/2016 | - | Initiated Coverage | Buy | $40.00 | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 4/25/2016 |
VNRX VolitionRX | $0.68
+2.5% | 4/21/2016 | Ram Selvaraju | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 4/21/2016 |
Forget Tesla — This Tiny AI Stock Is Musk’s Real Play (Ad) While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it could transform warfare, robotics, and the global economy. But you don’t need to buy Tesla or wait for xAI to IPO to benefit.
One overlooked public company is supplying the critical tech behind Musk’s AI push — and it trades for a fraction of Nvidia’s price. Hedge funds are already loading up, but most investors haven’t noticed yet. See the full details on this “backdoor” Musk bet here |
ABEO Abeona Therapeutics | $6.87
+0.2% | 4/20/2016 | - | Reiterated Rating | Buy | $425.00 | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 4/20/2016 |
MBOT Microbot Medical | $3.61
-3.9% | 4/20/2016 | - | Initiated Coverage | Buy | $18.00 | View details for Rodman & Renshaw rating of Microbot Medical (NASDAQ:MBOT) on 4/20/2016 |
AG First Majestic Silver | $9.37
-2.5% | 4/15/2016 | - | Boost Price Target | Buy | $6.00 -> $8.75 | View details for Rodman & Renshaw rating of First Majestic Silver (NYSE:AG) on 4/15/2016 |
SMLR Semler Scientific | $28.93
-1.5% | 4/15/2016 | - | Initiated Coverage | Buy | $8.00 | View details for Rodman & Renshaw rating of Semler Scientific (NASDAQ:SMLR) on 4/15/2016 |
EXK Endeavour Silver | $6.37
-2.0% | 4/12/2016 | - | Boost Price Target | Buy | $2.50 -> $3.40 | View details for Rodman & Renshaw rating of Endeavour Silver (NYSE:EXK) on 4/12/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 4/11/2016 | Ram Selvaraju | Lower Price Target | Buy | $118.00 -> $105.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 4/11/2016 |
INO Inovio Pharmaceuticals | $2.65
+2.9% | 4/9/2016 | - | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 4/9/2016 |
VNRX VolitionRX | $0.68
+2.5% | 4/9/2016 | Ram Selvaraju | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 4/9/2016 |
EKSO Ekso Bionics | $4.11
+4.1% | 4/5/2016 | - | Reiterated Rating | Buy | $4,725.00 | View details for Rodman & Renshaw rating of Ekso Bionics (NASDAQ:EKSO) on 4/5/2016 |
KURA Kura Oncology | $8.25
+3.8% | 4/4/2016 | - | Initiated Coverage | Buy | $52,500.00 | View details for Rodman & Renshaw rating of Kura Oncology (NASDAQ:KURA) on 4/4/2016 |
PLX Protalix BioTherapeutics | $1.64
-0.3% | 4/4/2016 | - | Initiated Coverage | Buy | $35.00 | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/4/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 4/3/2016 | Ram Selvaraju | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 4/3/2016 |
AMSC American Superconductor | $49.18
+0.9% | 4/1/2016 | Amit Dayal | Reiterated Rating | Neutral | | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 4/1/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 3/28/2016 | Ram Selvaraju | Reiterated Rating | Buy | $118.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/28/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 3/22/2016 | Ram Selvaraju | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/22/2016 |
NNDM Nano Dimension | $1.38
+1.1% | 3/21/2016 | - | Initiated Coverage | Buy | $700.00 | View details for Rodman & Renshaw rating of Nano Dimension (NASDAQ:NNDM) on 3/21/2016 |
INO Inovio Pharmaceuticals | $2.65
+2.9% | 3/20/2016 | - | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 3/20/2016 |
UUUU Energy Fuels | $11.41
+0.4% | 3/17/2016 | - | Lower Price Target | Buy | $6.90 -> $6.30 | View details for Rodman & Renshaw rating of Energy Fuels (NYSEAMERICAN:UUUU) on 3/17/2016 |
CRMD CorMedix | $14.20
-3.0% | 3/17/2016 | - | Boost Price Target | Buy | $32.50 -> $37.50 | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 3/17/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 3/16/2016 | Ram Selvaraju | Lower Price Target | Buy | $150.00 -> $118.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/16/2016 |
MUX McEwen | $13.95
+1.2% | 3/14/2016 | - | Boost Price Target | | $13.00 -> $24.00 | View details for Rodman & Renshaw rating of McEwen (NYSE:MUX) on 3/14/2016 |
VNRX VolitionRX | $0.68
+2.5% | 3/14/2016 | - | Reiterated Rating | Buy | $12.00 | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 3/14/2016 |
INSG Inseego | $12.72
-1.7% | 3/7/2016 | - | Lower Price Target | Buy | $60.00 -> $30.00 | View details for Rodman & Renshaw rating of Inseego (NASDAQ:INSG) on 3/7/2016 |
PLM PolyMet Mining | $2.10
-0.5% | 3/4/2016 | - | Boost Price Target | Buy | $2.00 -> $2.40 | View details for Rodman & Renshaw rating of PolyMet Mining (NYSEAMERICAN:PLM) on 3/4/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 3/2/2016 | Ram Selvaraju | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 3/2/2016 |
AG First Majestic Silver | $9.37
-2.5% | 2/29/2016 | - | Initiated Coverage | Buy | $6.00 | View details for Rodman & Renshaw rating of First Majestic Silver (NYSE:AG) on 2/29/2016 |
EXK Endeavour Silver | $6.37
-2.0% | 2/29/2016 | - | Initiated Coverage | Buy | $2.50 | View details for Rodman & Renshaw rating of Endeavour Silver (NYSE:EXK) on 2/29/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 2/23/2016 | Ram Selvaraju | Reiterated Rating | Buy | $150.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 2/23/2016 |
RDCM Radcom | $13.23
+0.5% | 2/18/2016 | - | Boost Price Target | Buy | $12.00 -> $16.00 | View details for Rodman & Renshaw rating of Radcom (NASDAQ:RDCM) on 2/18/2016 |
BHC Bausch Health Cos | $7.44
-3.2% | 2/16/2016 | - | Initiated Coverage | Buy | $150.00 | View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 2/16/2016 |
TMQ Trilogy Metals | $1.61
-0.9% | 2/11/2016 | - | Reiterated Rating | Buy | $1.40 -> $1.30 | View details for Rodman & Renshaw rating of Trilogy Metals (NYSEAMERICAN:TMQ) on 2/11/2016 |
TMQ Trilogy Metals | $1.61
-0.9% | 2/10/2016 | - | Lower Price Target | Buy | $1.40 -> $1.30 | View details for Rodman & Renshaw rating of Trilogy Metals (NYSEAMERICAN:TMQ) on 2/10/2016 |
BCRX BioCryst Pharmaceuticals | $8.07
-2.7% | 2/9/2016 | - | Lower Price Target | Buy | $24.00 -> $10.00 | View details for Rodman & Renshaw rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) on 2/9/2016 |
VNRX VolitionRX | $0.68
+2.5% | 2/1/2016 | - | Initiated Coverage | Buy | $12.00 | View details for Rodman & Renshaw rating of VolitionRX (NYSEAMERICAN:VNRX) on 2/1/2016 |
INO Inovio Pharmaceuticals | $2.65
+2.9% | 1/29/2016 | - | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 1/29/2016 |
IPWR Ideal Power | $5.27
+2.5% | 1/26/2016 | - | Initiated Coverage | Buy | $12.00 | View details for Rodman & Renshaw rating of Ideal Power (NASDAQ:IPWR) on 1/26/2016 |
AMSC American Superconductor | $49.18
+0.9% | 1/13/2016 | - | Initiated Coverage | Buy | $10.00 | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 1/13/2016 |
ORMP Oramed Pharmaceuticals | $2.19
+1.6% | 1/10/2016 | - | Reiterated Rating | Buy | $25.00 | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 1/10/2016 |
GGD GoGold Resources | C$2.64
+5.2% | 12/21/2015 | - | Boost Price Target | | C$2.70 -> C$2.90 | View details for Rodman & Renshaw rating of GoGold Resources (TSE:GGD) on 12/21/2015 |
MVIS Microvision | $1.13
-1.3% | 12/17/2015 | - | Initiated Coverage | Buy | $3.50 | View details for Rodman & Renshaw rating of Microvision (NASDAQ:MVIS) on 12/17/2015 |
CRMD CorMedix | $14.20
-3.0% | 12/16/2015 | - | Initiated Coverage | Buy | | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 12/16/2015 |
VUZI Vuzix | $2.08
-3.5% | 12/10/2015 | - | Initiated Coverage | Buy | $10.00 | View details for Rodman & Renshaw rating of Vuzix (NASDAQ:VUZI) on 12/10/2015 |
CRMD CorMedix | $14.20
-3.0% | 11/12/2015 | - | Initiated Coverage | Buy | $32.50 | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 11/12/2015 |
BLDP Ballard Power Systems | $1.93
+3.5% | 10/5/2015 | - | Reiterated Rating | Buy | | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 10/5/2015 |
ORMP Oramed Pharmaceuticals | $2.19
+1.6% | 10/1/2015 | - | Initiated Coverage | Buy | $24.00 | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 10/1/2015 |
BLDP Ballard Power Systems | $1.93
+3.5% | 8/20/2015 | - | Initiated Coverage | Buy | $2.50 | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 8/20/2015 |
GEVO Gevo | $1.67
-3.2% | 8/19/2015 | - | Initiated Coverage | Buy | $100.00 | View details for Rodman & Renshaw rating of Gevo (NASDAQ:GEVO) on 8/19/2015 |
EFOI Energy Focus | $2.62
+3.1% | 8/7/2015 | - | Initiated Coverage | Buy | $630.00 | View details for Rodman & Renshaw rating of Energy Focus (NASDAQ:EFOI) on 8/7/2015 |
BLDP Ballard Power Systems | $1.93
+3.5% | 7/14/2015 | - | Initiated Coverage | Buy | | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 7/14/2015 |
EFOI Energy Focus | $2.62
+3.1% | 6/25/2015 | - | Initiated Coverage | Buy | | View details for Rodman & Renshaw rating of Energy Focus (NASDAQ:EFOI) on 6/25/2015 |
"I'm risking my reputation on this" (Ad) A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year.
That's why we've rushed to update our book "Crypto Revolution" – to show you exactly how to position yourself for this historic opportunity. Click here to claim your FREE copy now! |
CPRX Catalyst Pharmaceuticals | $19.74
-3.9% | 8/27/2012 | - | Upgrade | Market Perform -> Outperform | $3.70 | View details for Rodman & Renshaw rating of Catalyst Pharmaceuticals (NASDAQ:CPRX) on 8/27/2012 |
CYTK Cytokinetics | $48.39
-2.5% | 7/31/2012 | - | Reiterated Rating | Outperform | $2.00 | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 7/31/2012 |
ALNY Alnylam Pharmaceuticals | $446.75
-0.1% | 7/31/2012 | - | Reiterated Rating | Outperform | $22.00 | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 7/31/2012 |
BMY Bristol Myers Squibb | $47.61
+0.4% | 7/27/2012 | - | Boost Price Target | Outperform | $38.00 -> $39.50 | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 7/27/2012 |
AMGN Amgen | $283.53
-1.2% | 7/23/2012 | - | Boost Price Target | Outperform | $73.00 -> $89.00 | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 7/23/2012 |
ALNY Alnylam Pharmaceuticals | $446.75
-0.1% | 7/16/2012 | - | Reiterated Rating | Outperform | | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 7/16/2012 |
ALGT Allegiant Travel | $64.68
+0.3% | 7/13/2012 | - | Boost Price Target | Outperform | $72.00 -> $79.00 | View details for Rodman & Renshaw rating of Allegiant Travel (NASDAQ:ALGT) on 7/13/2012 |
BMY Bristol Myers Squibb | $47.61
+0.4% | 7/5/2012 | - | Reiterated Rating | Market Perform | $38.00 | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 7/5/2012 |
ASMB Assembly Biosciences | $23.75
-1.6% | 6/26/2012 | - | Lower Price Target | | $132.00 | View details for Rodman & Renshaw rating of Assembly Biosciences (NASDAQ:ASMB) on 6/26/2012 |
RPMT Virtual Piggy | $0.43
-1.4% | 6/25/2012 | - | Initiated Coverage | Outperform | $5.00 | View details for Rodman & Renshaw rating of Virtual Piggy (OTCMKTS:RPMT) on 6/25/2012 |
AMGN Amgen | $283.53
-1.2% | 6/21/2012 | - | Boost Price Target | Outperform | $57.00 -> $73.00 | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 6/21/2012 |
DCO Ducommun | $90.11
-0.9% | 5/24/2012 | - | Initiated Coverage | Market Perform | | View details for Rodman & Renshaw rating of Ducommun (NYSE:DCO) on 5/24/2012 |
POWL Powell Industries | $258.65
-1.9% | 5/10/2012 | - | Upgrade | Market Perform -> Outperform | $43.00 | View details for Rodman & Renshaw rating of Powell Industries (NASDAQ:POWL) on 5/10/2012 |
NPO Enpro | $213.04
-0.9% | 5/4/2012 | - | Boost Price Target | Outperform | $47.00 -> $50.00 | View details for Rodman & Renshaw rating of Enpro (NYSE:NPO) on 5/4/2012 |
RMTI Rockwell Medical | $1.77
-3.5% | 4/24/2012 | - | Initiated Coverage | Outperform | $176.00 | View details for Rodman & Renshaw rating of Rockwell Medical (NASDAQ:RMTI) on 4/24/2012 |
SYK Stryker | $385.52
-1.1% | 4/20/2012 | - | Downgrade | Outperform -> Market Perform | | View details for Rodman & Renshaw rating of Stryker (NYSE:SYK) on 4/20/2012 |
PODD Insulet | $339.39
-1.6% | 4/18/2012 | - | Upgrade | Market Perform -> Outperform | | View details for Rodman & Renshaw rating of Insulet (NASDAQ:PODD) on 4/18/2012 |
TRS TriMas | $38.78
+2.1% | 3/15/2012 | - | Initiated Coverage | Outperform | $32.00 | View details for Rodman & Renshaw rating of TriMas (NASDAQ:TRS) on 3/15/2012 |
OMER Omeros | $4.10
-4.5% | 3/13/2012 | - | Boost Price Target | Outperform | $13.00 -> $16.00 | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 3/13/2012 |
AMGN Amgen | $283.53
-1.2% | 3/7/2012 | - | Reiterated Rating | Outperform | $57.00 | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 3/7/2012 |
VSTM Verastem | $9.17
-0.6% | 3/7/2012 | - | Initiated Coverage | Buy -> Market Perform | | View details for Rodman & Renshaw rating of Verastem (NASDAQ:VSTM) on 3/7/2012 |
ANIP ANI Pharmaceuticals | $93.59
-0.5% | 2/27/2012 | - | Reiterated Rating | Market Perform | | View details for Rodman & Renshaw rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 2/27/2012 |
MDGL Madrigal Pharmaceuticals | $427.36
-2.0% | 2/22/2012 | - | Reiterated Rating | Market Perform | $8.00 | View details for Rodman & Renshaw rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 2/22/2012 |
MGIC Magic Software Enterprises | $19.34
+0.2% | 2/15/2012 | - | Boost Price Target | Outperform | $8.00 -> $10.00 | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 2/15/2012 |
ALNY Alnylam Pharmaceuticals | $446.75
-0.1% | 2/6/2012 | - | Boost Price Target | Outperform | $19.00 | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 2/6/2012 |
DAL Delta Air Lines | $61.66
+0.9% | 2/6/2012 | - | Reiterated Rating | Outperform | $14.00 | View details for Rodman & Renshaw rating of Delta Air Lines (NYSE:DAL) on 2/6/2012 |
ALGT Allegiant Travel | $64.68
+0.3% | 2/2/2012 | - | Boost Price Target | | $62.00 | View details for Rodman & Renshaw rating of Allegiant Travel (NASDAQ:ALGT) on 2/2/2012 |
POWL Powell Industries | $258.65
-1.9% | 1/26/2012 | - | Initiated Coverage | Market Perform | | View details for Rodman & Renshaw rating of Powell Industries (NASDAQ:POWL) on 1/26/2012 |
SILC Silicom | $16.26
+0.6% | 1/24/2012 | - | Boost Price Target | Outperform | $20.00 -> $25.00 | View details for Rodman & Renshaw rating of Silicom (NASDAQ:SILC) on 1/24/2012 |
BMY Bristol Myers Squibb | $47.61
+0.4% | 1/23/2012 | - | Reiterated Rating | Outperform | $51.00 | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 1/23/2012 |
LUV Southwest Airlines | $32.40
+1.0% | 1/20/2012 | - | Reiterated Rating | Outperform | $12.00 | View details for Rodman & Renshaw rating of Southwest Airlines (NYSE:LUV) on 1/20/2012 |
AMGN Amgen | $283.53
-1.2% | 1/17/2012 | - | Reiterated Rating | Outperform | $57.00 | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 1/17/2012 |
MDGL Madrigal Pharmaceuticals | $427.36
-2.0% | 1/5/2012 | - | Initiated Coverage | Outperform | $8.00 | View details for Rodman & Renshaw rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 1/5/2012 |
ALNY Alnylam Pharmaceuticals | $446.75
-0.1% | 1/4/2012 | - | Reiterated Rating | Outperform | $12.00 | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 1/4/2012 |
WWD Woodward | $244.23
-0.7% | 1/4/2012 | - | Initiated Coverage | Outperform | $52.00 | View details for Rodman & Renshaw rating of Woodward (NASDAQ:WWD) on 1/4/2012 |
AMGN Amgen | $283.53
-1.2% | 12/23/2011 | - | Reiterated Rating | Outperform | $57.00 | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 12/23/2011 |
ANIP ANI Pharmaceuticals | $93.59
-0.5% | 12/15/2011 | - | Downgrade | Outperform -> Market Perform | | View details for Rodman & Renshaw rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 12/15/2011 |
INTC Intel | $23.95
-1.1% | 12/13/2011 | - | Reiterated Rating | Outperform | $27.00 | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 12/13/2011 |
BMY Bristol Myers Squibb | $47.61
+0.4% | 12/13/2011 | - | Lower Price Target | | $51.00 | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 12/13/2011 |
ALNY Alnylam Pharmaceuticals | $446.75
-0.1% | 12/12/2011 | - | Reiterated Rating | Outperform | $12.00 | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 12/12/2011 |
BMY Bristol Myers Squibb | $47.61
+0.4% | 12/12/2011 | - | Reiterated Rating | Outperform | $52.50 | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 12/12/2011 |
OMER Omeros | $4.10
-4.5% | 12/5/2011 | - | Upgrade | Market Perform -> Outperform | $13.00 | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 12/5/2011 |
ROG Rogers | $78.12
+1.0% | 12/2/2011 | - | Initiated Coverage | Outperform | $55.00 | View details for Rodman & Renshaw rating of Rogers (NYSE:ROG) on 12/2/2011 |
ALNY Alnylam Pharmaceuticals | $446.75
-0.1% | 12/1/2011 | - | Reiterated Rating | Outperform | | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 12/1/2011 |
AMGN Amgen | $283.53
-1.2% | 12/1/2011 | - | Initiated Coverage | Outperform | $62.00 | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 12/1/2011 |
CRIS Curis | $1.69
+3.3% | 11/30/2011 | - | Reiterated Rating | Outperform | $600.00 | View details for Rodman & Renshaw rating of Curis (NASDAQ:CRIS) on 11/30/2011 |
EW Edwards Lifesciences | $80.77
-1.2% | 11/29/2011 | - | Reiterated Rating | Market Perform | | View details for Rodman & Renshaw rating of Edwards Lifesciences (NYSE:EW) on 11/29/2011 |
AAPL Apple | $237.19
+3.3% | 11/29/2011 | - | Reiterated Rating | Outperform | $16.07 | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 11/29/2011 |
LUV Southwest Airlines | $32.40
+1.0% | 11/21/2011 | - | Reiterated Rating | Outperform | $12.00 | View details for Rodman & Renshaw rating of Southwest Airlines (NYSE:LUV) on 11/21/2011 |
DELL Dell Technologies | $123.53
+2.1% | 11/15/2011 | - | Reiterated Rating | Outperform | $18.00 | View details for Rodman & Renshaw rating of Dell Technologies (NYSE:DELL) on 11/15/2011 |
EW Edwards Lifesciences | $80.77
-1.2% | 11/11/2011 | - | Reiterated Rating | Market Perform | | View details for Rodman & Renshaw rating of Edwards Lifesciences (NYSE:EW) on 11/11/2011 |
ADNT Adient | $24.28
-0.7% | 11/11/2011 | - | Initiated Coverage | Market Perform | | View details for Rodman & Renshaw rating of Adient (NYSE:ADNT) on 11/11/2011 |
ALNY Alnylam Pharmaceuticals | $446.75
-0.1% | 11/10/2011 | - | Reiterated Rating | Outperform | | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 11/10/2011 |
INTC Intel | $23.95
-1.1% | 11/10/2011 | - | Reiterated Rating | Outperform | | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 11/10/2011 |
CRIS Curis | $1.69
+3.3% | 11/10/2011 | - | Reiterated Rating | Outperform | $600.00 | View details for Rodman & Renshaw rating of Curis (NASDAQ:CRIS) on 11/10/2011 |
AAPL Apple | $237.19
+3.3% | 11/9/2011 | - | Reiterated Rating | Outperform | | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 11/9/2011 |
GERN Geron | $1.41
-4.4% | 11/9/2011 | - | Lower Price Target | | $4.00 | View details for Rodman & Renshaw rating of Geron (NASDAQ:GERN) on 11/9/2011 |
BMY Bristol Myers Squibb | $47.61
+0.4% | 11/9/2011 | - | Reiterated Rating | Outperform | $52.50 | View details for Rodman & Renshaw rating of Bristol Myers Squibb (NYSE:BMY) on 11/9/2011 |
USEG U.S. Energy | $1.18
+0.4% | 11/8/2011 | - | Reiterated Rating | Outperform | $47.50 | View details for Rodman & Renshaw rating of U.S. Energy (NASDAQ:USEG) on 11/8/2011 |
ERII Energy Recovery | $14.41
+0.5% | 11/4/2011 | - | Reiterated Rating | Market Perform | | View details for Rodman & Renshaw rating of Energy Recovery (NASDAQ:ERII) on 11/4/2011 |
